Lilly Isn't (Immediately) Worried About US Drug Pricing Legislation
Executive Summary
Government price 'negotiations' unlikely to be enacted in the near term, CEO Ricks tells investors, but reform of the Part D benefit also faces long odds, even though Lilly would support well designed changes.